AOD-9604 vs HGH Fragment 176-191
Both are derived from the fat-burning region of human growth hormone but differ in molecular modifications, stability, and research depth. AOD-9604 has more clinical trial data while HGH Frag is the unmodified lipolytic fragment.
Last updated: 2026-03-08
AOD-9604 and HGH Fragment 176-191 are two closely related peptides that both derive from the lipolytic (fat-burning) region of human growth hormone — specifically amino acids 176-191 of the GH molecule. Despite sharing this origin, they are distinct compounds with meaningful differences in molecular structure, research history, and clinical development.
AOD-9604 (Anti-Obesity Drug 9604) is a modified version of this fragment, engineered by Metabolic Pharmaceuticals in Australia with a tyrosine residue added to improve stability and bioactivity. HGH Fragment 176-191 is the unmodified C-terminal fragment of growth hormone, retaining the native amino acid sequence.
Both peptides have been researched for their ability to stimulate lipolysis (fat breakdown) without the diabetogenic or growth-promoting effects of full-length growth hormone. This comparison examines the evidence for each compound.
**Important Note:** Neither AOD-9604 nor HGH Fragment 176-191 is approved for weight loss by the MHRA, EMA, or FDA. This comparison is for educational purposes based on published research.
Quick Comparison Table
| Category | AOD-9604 | HGH Fragment 176-191 |
|---|---|---|
| Origin | Modified C-terminal fragment of GH (aa 176-191 + Tyr) | Unmodified C-terminal fragment of GH (aa 176-191) |
| Molecular Weight | ~1817 Da | ~1815 Da |
| Primary Mechanism | β3-adrenergic receptor-mediated lipolysis | β3-adrenergic receptor-mediated lipolysis |
| Research Focus | Obesity, fat metabolism, cartilage repair | Fat metabolism, body recomposition |
| Clinical Trials | Phase IIb completed (Metabolic Pharmaceuticals) | No formal clinical trials |
| Half-Life | Estimated 30-60 minutes | Estimated 15-30 minutes |
| Oral Bioavailability | No (injection required) | No (injection required) |
| Regulatory Status (UK) | TGA-listed in Australia for health products; research compound in UK | Research compound only |
How They Work: Mechanism of Action
AOD-9604
AOD-9604 Mechanism:
AOD-9604 is the modified C-terminal fragment of human growth hormone with an added tyrosine residue at the N-terminus. Its lipolytic mechanism operates through several pathways:
1. **β3-Adrenergic Receptor Activation** AOD-9604 stimulates lipolysis through β3-adrenergic receptor signalling in adipose tissue, mimicking the fat-burning effects of full growth hormone without activating IGF-1 pathways.
2. **Lipase Stimulation** The peptide activates hormone-sensitive lipase (HSL) in adipocytes, promoting the breakdown of stored triglycerides into free fatty acids and glycerol.
3. **Anti-Lipogenic Effects** AOD-9604 inhibits lipogenesis (new fat formation) by reducing the activity of enzymes involved in fatty acid synthesis, including acetyl-CoA carboxylase.
4. **No IGF-1 Elevation** Critically, AOD-9604 does not raise IGF-1 levels or produce growth-promoting effects, making it more targeted than full GH for fat loss applications.
5. **Cartilage Repair Properties** More recent research has identified potential chondroprotective effects, with AOD-9604 showing promise for osteoarthritis through stimulation of proteoglycan synthesis.
HGH Fragment 176-191
HGH Fragment 176-191 Mechanism:
HGH Fragment 176-191 is the unmodified C-terminal portion of human growth hormone, retaining the native sequence responsible for GH's lipolytic activity:
1. **β3-Adrenergic Receptor Activation** Like AOD-9604, HGH Frag stimulates lipolysis through β3-adrenergic receptor pathways in white adipose tissue, promoting fat mobilisation.
2. **Hormone-Sensitive Lipase Activation** The fragment activates HSL to break down stored triglycerides, similar to the lipolytic action of full-length GH but without the growth-promoting effects.
3. **Inhibition of Lipogenesis** HGH Frag inhibits de novo lipogenesis, reducing the conversion of carbohydrates and other substrates into new fat stores.
4. **No Diabetogenic Effects** Unlike full-length growth hormone, the fragment does not impair glucose metabolism or insulin sensitivity, making it theoretically safer for metabolic research.
5. **Direct Adipocyte Effects** The peptide acts directly on adipocyte receptors without requiring conversion to IGF-1, providing a more targeted mechanism for fat metabolism research.
Clinical Trial Evidence
AOD-9604 Clinical Studies
Design: Review
) and non-peptidic (selective androgen receptor modulators, hypoxia-inducible factor stabilizers, siRNA, S-107 and ARM036/aladorian, etc. ) as well as inorganic (cobalt) nature are considered and discussed in terms of specific requirements originating from physicochemical properties, concentration levels, metabolism, and their amenability for chromatographic-mass spectrometric or alternative detection methods.
View study — PubMed 24906629Design: Review
Of these, only rimonabant has got as far as completing phase III clinical trials. This review will provide an overview of the most prominent drugs currently undergoing clinical development as potential anti-obesity therapies.
View study — PubMed 16625817Design: Review
Uk Metabolic is developing AOD-9604 for the potential treatment of obesity. By February 2002, phase IIa trials were underway.
View study — PubMed 15134286Design: Study
The stability of the peptides in urine was tested, and -20°C was found to be the appropriate storage temperature for sports drug testing. Finally, proof-of-concept was shown by analysing elimination study urine samples collected from individuals having administered GHRP-6, GHRP-2, or LHRH.
View study — PubMed 26578461HGH Fragment 176-191 Clinical Studies
Design: Study
These dual-loaded Chitosan nanoparticles demonstrated greater anti-proliferative activity against a breast cancer cell line (MCF-7) than doxorubicin-loaded Chitosan. This dual-loading strategy may enhance the anticancer potency of doxorubicin and reduce the clinical side effects associated with non-target tissue exposure.
View study — PubMed 35783198Benefits Comparison
AOD-9604 Unique Benefits
- Human clinical trial data (Phase IIb completed with 300+ subjects)
- Demonstrated oral bioavailability in some formulations
- Additional cartilage repair/chondroprotective properties identified
- TGA-listed in Australia as an approved ingredient in health products
- Better stability profile due to tyrosine modification
- More extensive safety data from controlled human trials
Shared Benefits
- Stimulate lipolysis without IGF-1 elevation or growth effects
- No diabetogenic effects (unlike full-length GH)
- Target adipose tissue specifically
- Inhibit lipogenesis (new fat formation)
- Do not affect lean muscle mass or bone growth
- Generally well-tolerated in research settings
HGH Fragment 176-191 Unique Benefits
- Native GH sequence — no synthetic modifications
- Potent lipolytic activity at very low concentrations
- Simpler molecular structure — easier to synthesise
- Well-characterised mechanism as part of GH research
- Lower cost due to simpler synthesis
- Foundational research that led to AOD-9604 development
Research & Evidence
AOD-9604 Research
AOD-9604 Research Evidence:
AOD-9604 was developed by Metabolic Pharmaceuticals Ltd in Melbourne, Australia, specifically as an anti-obesity therapeutic derived from growth hormone.
Key Research Areas:
Obesity/Fat Loss - Phase IIb clinical trial with 300 obese subjects showed statistically significant fat loss - Dose-dependent effects on fat oxidation established - No effects on IGF-1, glucose metabolism, or insulin sensitivity
Cartilage Repair - More recent research shows chondroprotective effects - Stimulates proteoglycan and collagen synthesis in cartilage cells - TGA-listed in Australia for health products (topical/oral joint formulations)
Safety - Extensive human safety data from clinical trials - No serious adverse events in controlled studies - FDA GRAS (Generally Recognised As Safe) designation for food use
Limitations: - Phase III trials were not completed (company funding issues, not safety concerns) - Most fat loss data is from early 2000s - Cartilage repair research is still early-stage
HGH Fragment 176-191 Research
HGH Fragment 176-191 Research Evidence:
HGH Fragment 176-191 research is primarily preclinical, originating from fundamental growth hormone biology studies.
Key Research Areas:
Lipolysis Mechanism - Identified as the specific region of GH responsible for fat metabolism - Potent lipolytic activity demonstrated in multiple in vitro models - Acts through β3-adrenergic receptor pathway
Animal Studies - Significant fat reduction in obese mouse models - No effects on blood glucose, insulin, or IGF-1 - Selective fat reduction without lean mass changes
Mechanistic Studies - Confirmed separation of GH's lipolytic and growth-promoting activities - Dual mechanism: stimulates lipolysis AND inhibits lipogenesis
Limitations: - No human clinical trials conducted - All evidence is preclinical (in vitro and animal) - Stability and half-life are limited compared to AOD-9604 - Less commercially developed
Head-to-Head Analysis
Direct Comparison:
AOD-9604 is essentially an improved version of HGH Fragment 176-191, so direct comparison reflects an evolution rather than a competition.
Evidence Quality: - AOD-9604 has Phase IIb human clinical trial data — significantly stronger evidence - HGH Fragment has foundational preclinical data that informed AOD-9604's development - Neither has completed Phase III trials
Key Difference: AOD-9604's tyrosine modification provides improved stability and potentially enhanced receptor binding compared to the unmodified fragment. This modification was specifically engineered to create a more viable therapeutic candidate.
Practical Consideration: HGH Fragment 176-191 is more widely available in the research peptide market and is typically less expensive, but lacks the clinical validation of AOD-9604.
Protocol Comparison
AOD-9604 Protocol
AOD-9604 Theoretical Protocols (Research-Based):
Dosing: Clinical trials used oral doses of 0.25-1mg/day. Injectable research doses commonly cited are 250-500 mcg/day. No established therapeutic dose.
Routes: - Subcutaneous injection (most common in research) - Oral administration (explored in clinical trials with lower bioavailability)
Duration: Clinical trials ran 12-24 weeks. No established human protocol duration.
Timing: Often administered in the morning on an empty stomach to maximise lipolytic effect during fasting state.
⚠️ Disclaimer: These are extrapolations from research data. No approved protocols exist.
HGH Fragment 176-191 Protocol
HGH Fragment 176-191 Theoretical Protocols (Research-Based):
Dosing: No human dosing data exists. Commonly cited research doses are 250-500 mcg/day, extrapolated from animal studies and AOD-9604 clinical data.
Routes: - Subcutaneous injection only - Not orally bioavailable
Duration: No established duration. Commonly discussed as 8-12 week research cycles.
Timing: Typically administered pre-fasting or before exercise to capitalise on lipolytic window. Short half-life may require twice-daily dosing.
⚠️ Disclaimer: No human clinical data exists for HGH Fragment 176-191 dosing.
Combined Use
Theoretical Combined Use:
Combining AOD-9604 and HGH Fragment 176-191 is generally not considered useful as they target the same receptor pathway — the β3-adrenergic lipolytic mechanism.
Rationale Against Combination: - Both derive from the same region of GH and act on the same receptors - Combining would likely produce receptor competition rather than synergy - No theoretical or practical basis for additive effects
Alternative Combinations: Researchers more commonly explore pairing either peptide with complementary fat loss compounds targeting different pathways (e.g., GLP-1 agonists, thyroid peptides).
⚠️ Combined use has no scientific basis and is not recommended.
Safety Profiles
AOD-9604 Safety
AOD-9604 Safety Profile:
Clinical Trial Data: - Phase IIb trial: safety profile comparable to placebo - No serious adverse events in 300+ human subjects - No effects on blood glucose, insulin, or IGF-1 levels - FDA GRAS designation for food use
Potential Concerns: - Long-term effects beyond 24 weeks unknown - Limited post-market surveillance data - Quality control varies for research-grade sources
Reported Side Effects: - Injection site reactions (mild, transient) - Headache (uncommon) - Generally very well tolerated
Regulatory: TGA-listed in Australia. Research compound in UK/EU. Not approved for weight loss anywhere.
HGH Fragment 176-191 Safety
HGH Fragment 176-191 Safety Profile:
Preclinical Data: - Well-tolerated in animal studies at lipolytic doses - No diabetogenic effects observed - No effects on growth markers or IGF-1
Potential Concerns: - No human safety data available - Shorter half-life may lead to inconsistent plasma levels - Quality and purity of research sources vary widely - Unknown long-term effects
Theoretical Side Effects: - Injection site reactions - Potential for transient hypoglycaemia (not observed in animal studies)
Regulatory: Research compound only. Not approved for human use in any jurisdiction. WADA prohibited substance.
The Verdict: When to Choose Which?
Choose AOD-9604 When:
- When evidence quality matters — AOD-9604 has Phase IIb human clinical trial data
- When cartilage repair or joint health is also a research interest
- When stability and longer half-life are important considerations
- When a more commercially validated compound is preferred
- When oral administration is being explored as a route
Choose HGH Fragment 176-191 When:
- When studying the native GH lipolytic mechanism without synthetic modifications
- When budget constraints favour a simpler, less expensive peptide
- When foundational mechanistic research is the priority
- When the unmodified GH fragment sequence is specifically required
Consider Combining When:
- Combination is generally not recommended — both target the same pathway
- Would likely produce receptor competition rather than synergy
- No research supports combining these two fragments
- Consider pairing either with complementary-mechanism peptides instead
Frequently Asked Questions
Conclusion
AOD-9604 and HGH Fragment 176-191 represent two generations of the same concept — isolating the fat-burning capability of growth hormone from its growth-promoting and diabetogenic effects. AOD-9604 is the clear leader in terms of evidence, with Phase IIb human clinical data, improved molecular stability, and additional chondroprotective properties. HGH Fragment 176-191 is the foundational molecule that inspired AOD-9604's development and remains relevant for mechanistic research. For fat loss research, AOD-9604 provides the stronger evidence base, while HGH Fragment offers a simpler, more accessible option for basic research.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither AOD-9604 nor HGH Fragment 176-191 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.